Therefore, the inversion of the signature of the proteins involved in this pathway (e.g., S1PR1, actin, 14-3-3s, S100-A9/8, myosin, S100A6), but also of the proteins involved in cell migration (e.g., αLβ2, ITGB1, DESG1) should be considered in novel therapeutic options of CLL. This evidence concerns the gene AFM and B-cell chronic lymphocytic leukemia.